Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Respiratory Syncytial Virus Infections 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Temozolomide 45Radiotherapy 17Magnetic Resonance Spectroscopy 17Specimen Handling 14Bevacizumab 12pembrolizumab 11Lomustine 9Radiation 8fludarabine 7Cyclophosphamide 7atezolizumab 4Biopsy 4olaparib 3Transurethral Resection of Bladder 3Surgical Procedures, Operative 3Nivolumab 3Leukapheresis 3D2C7-(scdsFv)-PE38KDEL 3Blood Specimen Collection 3Aminolevulinic Acid 3regorafenib 2fluciclovine F-18 2contrast agent BR1 2antisecretory factor 2abemaciclib 2Restraint, Physical 2Re-Irradiation 2Radiation Dose Hypofractionation 2Palliative Care 2Oncolytic Virotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Glioblastoma × Suspensions × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡